Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)
Sponsors and Collaborators
Robert Figlin, MD, FACP, Cedars-Sinai Medical Center
Christopher G Wood, MD, FACP, M.D. Anderson Cancer Center
Next post in Renal Cell Carcinoma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.